Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
0.7267
-0.0205 (-2.74%)
At close: Jun 23, 2025, 4:00 PM
0.7299
+0.0032 (0.44%)
After-hours: Jun 23, 2025, 7:59 PM EDT
Coherus Oncology Stock Forecast
CHRS's stock price has decreased by -56.49% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Coherus Oncology stock have a consensus rating of "Buy" and an average price target of $4.68, which forecasts a 544.01% increase in the stock price over the next year. The lowest target is $1.05 and the highest is $7.
Price Target: $4.68 (+544.01%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 29, 2025.
Analyst Ratings
The average analyst rating for Coherus Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +863.26% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | +44.49% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +863.26% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +863.26% | Jan 23, 2025 |
| Baird | Baird | Buy Maintains $4 → $6 | Buy | Maintains | $4 → $6 | +725.65% | Dec 5, 2024 |
Financial Forecast
Revenue This Year
57.19M
from 266.96M
Decreased by -78.58%
Revenue Next Year
118.13M
from 57.19M
Increased by 106.56%
EPS This Year
-1.17
from 0.25
EPS Next Year
-0.75
from -1.17
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 91.9M | 196.0M | 185.6M | ||
| Avg | 57.2M | 118.1M | 125.2M | ||
| Low | 41.2M | 60.8M | 88.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -65.6% | 242.8% | 57.1% | ||
| Avg | -78.6% | 106.6% | 6.0% | ||
| Low | -84.6% | 6.2% | -25.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.05 | -0.27 | -0.47 | ||
| Avg | -1.17 | -0.75 | -0.67 | ||
| Low | -1.21 | -1.13 | -0.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.